Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 40

Results For "EPL"

568 News Found

Corbevax to be administered to children between 12-14 years
News | March 14, 2022

Corbevax to be administered to children between 12-14 years

Govt announces vaccination programme for kids and those above 60 years of age


S.M.A.R.T. Radianz Vascular Stent System approved for transradial use in the U.S.
Medical Device | March 13, 2022

S.M.A.R.T. Radianz Vascular Stent System approved for transradial use in the U.S.

It signals Cordis' renewed investment in innovation


Daiichi Sankyo commits US $1 million humanitarian aid to Ukraine
Sustainability | March 11, 2022

Daiichi Sankyo commits US $1 million humanitarian aid to Ukraine

The money will be donated to the United Nations Children’s Fund (UNICEF)


Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals
interviews | March 10, 2022

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma


Ankura launches pharmaceutical data integrity solution
News | March 08, 2022

Ankura launches pharmaceutical data integrity solution

Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines


IOL Chemicals and Pharmaceuticals to limit capex at Rs 150 crore per year
News | March 07, 2022

IOL Chemicals and Pharmaceuticals to limit capex at Rs 150 crore per year

The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business


Cipla gets approval from SEC to conduct Paxlovid trials
News | March 03, 2022

Cipla gets approval from SEC to conduct Paxlovid trials

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations


DCGI approves Themis Medicare's Viralex for Covid-19 treatment
News | March 03, 2022

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections


Amrita University launches wearable device for home monitoring of glucose and BP
Digitisation | March 02, 2022

Amrita University launches wearable device for home monitoring of glucose and BP

Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home


Synapse Medicine raises US $ 28 million to scale its medication reconciliation platform
Startup | March 01, 2022

Synapse Medicine raises US $ 28 million to scale its medication reconciliation platform

The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States